Dr. Caroline C. Sigman, President and CEOA woman-owned small business, CCSA provides leading-edge advisory and regulatory services in product discovery and development. Over the years, the company has played a key role in designing industry-grade master protocols and investigational new drug applications (INDs) like those for Lung-MAP and I-SPY 2, which have been in use for over a decade. Backed by in-depth expertise, it empowers nimble biotech startups and major government institutions to lead every stage of clinical development with clarity and confidence.
“Our vast experience in handling regulatory affairs for several ground-breaking master protocols and INDs gives us a competitive edge,” says Linda A. Doody, Executive Director.
A highly skilled leadership team with deep scientific knowledge is at the heart of the company’s operations. Dr. Doody has been with CCSA for over 35 years and has built the regulatory and safety departments from the ground up. Its unparalleled scientific acumen is the result of government partnerships, including programs with the National Heart, Lung and Blood Institute (NHLBI) and NIH’s Blueprint Neurotherapeutics Network (BPN).
-5.jpg)
Many of CCSA’s commercial clients are referrals from previous government-sponsored collaborations. They rely on its hands-on approach and scientific depth to improve the odds of clinical trial success. In one instance, a company operating with a skeleton crew partnered with CCSA through the BPN program. Today, the company runs phase 3 trials in multiple countries, with CCSA supporting its U.S. regulatory strategy.
Long-term commitment is a core principle at CCSA. It guides early-stage innovators through complex clinical trials by staying on board beyond IND submission. Whether it’s ophthalmologic treatments, neurodegenerative disease therapeutics, cancer prevention or age-related drug development, the company delivers unparalleled scientific and strategic support throughout the entire R&D process.
-
Our vast experience in handling regulatory affairs for several ground-breaking master protocols and INDs gives us a competitive edge
“We very often function as members of our clients’ teams, integrating ourselves into projects and working very closely with clients’ staff,” says Dr. Caroline C. Sigman, President and CEO.
CCSA’s proficiency in managing INDs has been instrumental in conceptualizing and executing numerous master protocols. The I-SPY 2 platform’s transformational impact on breast cancer research is a perfect example. Designed to simultaneously evaluate multiple treatments using a shared control arm and adaptive design, I-SPY 2 delivers real-time insights and accelerates drug development.
Linda A. Doody, Executive DirectorThorough regulatory compliance is non-negotiable at CCSA. The decades-long history of interacting with various government agencies empowers it to execute successful filings with the FDA. Tapping into this expansive institutional memory, it also prepares clients for traditional FDA meetings and newer formats like Type D meetings to ensure that the client, agency and stakeholders are on the same page before trials begin.
Proactive collaboration with regulators is essential to maintaining the integrity of trials. The team prioritizes frequent and focused communication with agencies to maintain compliance with applicable regulations and ethically conduct trials.
CCSA’s foundation is built on the expertise of a 60-member team of toxicologists, chemists, pharmacologists and certified regulatory affairs professionals who work together to swiftly move projects from conception to approval. Their individual specializations are complemented by competency in medical writing, reinforced through training. The team works cohesively to review trial information and create well organized papers depicting the research trajectory and highlighting significant findings, providing clarity of objectives and allowing clients to secure faster drug approvals.
With scientists leading client interactions and drafting regulatory documents, CCSA guarantees accuracy in crucial submissions like IND, NDA and biologics license application (BLA) filings. All regulatory documentation is managed and maintained via electronic databases and web-based management systems.
To bridge the gap between science-led innovation and the reality of bringing a product to market, CCSA contributes to developing cost-effective dossiers of the highest integrity. In a rapidly changing landscape, where clinical trials become more adaptive and collaborative, CCSA continues to be the difference maker in bringing life-saving therapeutic medical products to market faster.
Choosing a Regulatory Partner for Complex Clinical Development
Regulatory consulting in healthcare has changed over the last few years. It is no longer enough for a firm to prepare filings at scheduled milestones and keep programs administratively on track. Today’s development environment moves too quickly for that. Clinical programs now involve adaptive trial models, emerging data expectations, novel mechanisms and far more interaction with regulators earlier in development. That has raised the bar for what sponsors should expect from a regulatory partner.
For executives evaluating providers, the real question is not whether a firm can submit documents. It is whether the team can help shape smarter development decisions before regulatory issues become expensive delays. Weak partners tend to operate downstream, reacting to problems once they surface. Stronger firms work much closer to the science, helping companies think through evidence strategy, protocol design, agency positioning and long-term submission planning from the beginning.
That distinction matters most in complex programs. Platform trials, umbrella studies, master protocols and government-supported development pathways create layers of operational and regulatory interdependence that traditional consulting models are not always built to manage. A single regulatory decision can affect study comparability, site readiness, safety oversight and even future expansion options for the program itself. In these settings, sponsors need advisors who understand how to preserve scientific consistency while keeping the regulatory path practical and defensible.
FDA interaction has also become more continuous and more consequential. Earlier engagement can reduce uncertainty, but only if sponsors enter those meetings with a disciplined strategy. Companies need to ask precise questions, frame evidence gaps carefully and avoid creating commitments that later limit development flexibility. Experienced regulatory teams play an important role here because they connect scientific rationale, clinical planning and submission timing into a coherent regulatory story rather than treating agency meetings as isolated events.
Another area executives often underestimate is continuity. Regulatory work does not happen in silos. Writing quality, safety documentation, eCTD readiness and cross-functional coordination all influence how clearly a development program is understood by reviewers. Providers that stay involved across multiple stages of development usually create far less rework later, particularly when early-stage assets begin transitioning toward pivotal or commercial planning.
CCS Associates is particularly well positioned for organizations that need science-driven regulatory support rather than basic submission management. The firm supports INDs, NDAs, ANDAs, IDEs, DMFs, CTAs, orphan drug designations and pre-IND meeting packages in eCTD format, but its value extends beyond documentation. Its experience includes work with master protocols, master IND structures, I-SPY 2, Lung-MAP, government-backed development programs and sponsors advancing from early clinical research into pivotal-stage development. For healthcare executives managing complex drug, biologic or device programs, CCS Associates stands out as a strong Gold Standard choice because of its combination of regulatory depth, scientific understanding and long-term program involvement.
...Read more
Regulatory Services Info
Q1
Why is CCS Associates recognized among Top Regulatory Services Providers?
CCS Associates is widely recognized due to its long-standing expertise in regulatory strategy, IND management and clinical development support. As a Regulatory Services Providers organization, it has contributed to more than 100 regulatory submissions including INDs, NDAs and IDEs across diverse therapeutic areas. Its involvement in landmark programs such as master protocol clinical trials highlights its ability to manage complex regulatory frameworks with precision and consistency.
Q2
What makes CCS Associates different from other Regulatory Services Providers?
CCS Associates stands out among Regulatory Services Providers because it combines scientific depth with hands-on regulatory execution. Its team includes toxicologists, pharmacologists, chemists and regulatory affairs specialists who directly contribute to submission development and clinical strategy. Instead of offering isolated consulting, it integrates into client programs as an operational extension, supporting everything from early study design to final regulatory approvals.
Q3
How does CCS Associates support drug development through Regulatory Services Providers expertise?
The company supports drug development by managing the full regulatory lifecycle, including pre-IND meetings, submission preparation and ongoing FDA communication. Within Regulatory Services Providers frameworks, CCS Associates ensures that Chemistry, Manufacturing and Controls (CMC), nonclinical and clinical documentation meet regulatory expectations. It also provides scientific and medical writing support, ensuring that submissions are both technically accurate and regulator-ready.
Q4
What role does regulatory strategy play in CCS Associates’ services?
Regulatory strategy is central to CCS Associates’ role as a Regulatory Services Providers firm. It develops structured pathways for product approval by aligning scientific development with regulatory requirements from the earliest stages. This includes designing IND strategies, preparing meeting packages for regulatory agencies and ensuring compliance with evolving FDA expectations. The approach helps reduce delays and improves the likelihood of successful submissions.
Q5
How does CCS Associates ensure quality and compliance in regulatory work?
Quality and compliance are maintained through structured review systems, electronic documentation management and cross-functional scientific oversight. As part of its Regulatory Services Providers model, CCS Associates applies rigorous validation to all regulatory documents before submission. Its internal quality assurance processes ensure that data integrity, formatting standards and regulatory requirements are consistently met across all client programs.
Q6
Why do biotech and pharmaceutical companies rely on CCS Associates as Regulatory Services Providers?
Companies rely on CCS Associates because it provides both scientific expertise and regulatory execution under one integrated framework. Its Regulatory Services Providers approach is particularly valuable for early-stage biotech firms that require structured guidance through complex FDA processes. The firm’s long-term engagement model ensures continuity across clinical phases, helping clients move from concept to approval with regulatory confidence.
